Literature DB >> 27302338

Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study.

J M Langley1, D M MacDougall2, B A Halperin3, A Swain4, S A Halperin3, K A Top3, S A McNeil3, D MacKinnon-Cameron3, K Marty5, G De Serres6, E Dubé6, J A Bettinger5.   

Abstract

An outbreak of Neisseria meningitidis serotype B infection occurred at a small residential university; public health announced an organizational vaccination program with the 4-component Meningococcal B (4CMenB) vaccine (Bexsero(TM), Novartis/GlaxoSmithKline Inc.) several days later. Since there were limited published data on reactogenicity of 4CMenB in persons over 17years of age, this study sought to conduct rapid surveillance of health events in vaccinees and controls using an online survey. Vaccine uptake was 84.7% for dose 1 (2967/3500) and 70% (2456/3500) for dose 2; the survey response rates were 33.0% (987/2967) and 18.7% (459/2456) in dose 1 and dose 1 recipients respectively, and 12% in unvaccinated individuals (63/533). Most students were 20-29years of age (vaccinees, 64.0%; controls, 74.0). A new health problem or worsening of an existing health problem was reported by 30.0% and 30.3% of vaccine recipients after doses 1 and 2 respectively; and by 15.9% of controls. These health problems interfered with the ability to perform normal activities in most vaccinees reporting these events (74.7% post dose 1; 62.6% post dose 2), and in 60% of controls. The health problems led to a health care provider visit (including emergency room) in 12.8% and 14.4% of vaccinees post doses 1 and 2, respectively and in 40% of controls. The most common reactions in vaccinees were injection site reactions (20.6% post dose 1, 16.1% post dose 20 and non-specific systemic complaints (22.6% post dose 1, 17.6% post dose 2). No hospitalizations were reported. An online surveillance program during an emergency meningococcal B vaccine program was successfully implemented, and detected higher rates of health events in vaccinees compared to controls, and high rates of both vaccinees and controls seeking medical attention. The types of adverse events reported by young adult vaccinees were consistent with those previously.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease outbreaks; Neisseria meningitidis group B; Student health services

Mesh:

Substances:

Year:  2016        PMID: 27302338     DOI: 10.1016/j.vaccine.2016.06.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

2.  Immunisation status and determinants of left-behind children aged 12-72 months in central China.

Authors:  Z L Ni; X D Tan; H Y Shao; Y Wang
Journal:  Epidemiol Infect       Date:  2017-03-30       Impact factor: 4.434

Review 3.  Participant-centred active surveillance of adverse events following immunisation: a narrative review.

Authors:  Patrick Cashman; Kristine Macartney; Gulam Khandaker; Catherine King; Michael Gold; David N Durrheim
Journal:  Int Health       Date:  2017-05-01       Impact factor: 2.473

4.  Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing.

Authors:  A R Giuliani; A Mattei; A Appetiti; D Pompei; F Di Donna; F Fiasca; L Fabiani
Journal:  Hum Vaccin Immunother       Date:  2018-06-21       Impact factor: 3.452

5.  Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.

Authors:  Femke van Kessel; Caroline van den Ende; Anouk M Oordt-Speets; Moe H Kyaw
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

6.  Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC).

Authors:  L Nicolosi; C Rizzo; G Castelli Gattinara; N Mirante; E Bellelli; C Bianchini; V Pansini; A Villani
Journal:  Ital J Pediatr       Date:  2019-10-30       Impact factor: 2.638

7.  Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1.

Authors:  Joanne M Langley; Soren Gantt; Caroline Quach; Julie A Bettinger; Scott A Halperin; Jill Mutch; Shelly A McNeil; Brian J Ward; Donna MacKinnon-Cameron; Lingyun Ye; Kim Marty; David Scheifele; Erin Brown; Joenel Alcantara
Journal:  Emerg Infect Dis       Date:  2020-03       Impact factor: 6.883

8.  Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.

Authors:  Marie-Claude Breton; Liping Huang; Sonya J Snedecor; Noelle Cornelio; Fiorella Fanton-Aita
Journal:  Can J Public Health       Date:  2020-01-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.